These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37444420)

  • 1. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
    Eichenauer DA; Fuchs M
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
    Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
    Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.
    Sidda A; Naleid NK; Manu G; Graffeo V; Jamil MO
    J Investig Med High Impact Case Rep; 2022; 10():23247096221111767. PubMed ID: 35861500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Savage KJ; Mottok A; Fanale M
    Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide.
    Siricilla M; Irwin L; Ferber A
    Case Rep Oncol Med; 2018; 2018():6137454. PubMed ID: 29552367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.
    Wang S; Medeiros LJ; Xu-Monette ZY; Zhang S; O'Malley DP; Orazi A; Zuo Z; Bueso-Ramos CE; Yin CC; Liu Z; Miranda RN; Young KH
    Ann Diagn Pathol; 2014 Aug; 18(4):203-9. PubMed ID: 24852241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
    Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
    J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma.
    Hartmann S; Eichenauer DA
    Pathology; 2020 Jan; 52(1):142-153. PubMed ID: 31785822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.